{"DataElement":{"publicId":"6346622","version":"1","preferredName":"Patient Hematoxylin and Eosin Staining Method Biospecimen Submission Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"Indication as to whether H&E stained slides were submitted.","longName":"HE_STN_MTD_SPEC_SUBM_IND","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"6346399","version":"1","preferredName":"Patient Hematoxylin and Eosin Staining Method Biospecimen Submission Clinical Trial Eligibility Criteria","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._Hematoxylin-and-eosin, or H&E, is a routine staining procedure of tissue sections. This staining method uses two separate dyes, one staining the nucleus and the other staining the cytoplasm and connective tissue. Hematoxylin is a dark purplish dye that stains the chromatin (nuclear material) within the nucleus. Eosin is an orangish-pink to red dye that stains the cytoplasmic material including connective tissue and collagen._Any material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes, including a sample obtained from a living organism or taken from the biological object after halting of all its life functions. Biospecimen can contain one or more components including but not limited to cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory products._The act of referring for judgment or consideration by others; the act of handing over something._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"2233604v1.0:6346401v1.0","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"2233604","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D847-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6346401","version":"1","preferredName":"Hematoxylin and Eosin Staining Method Biospecimen Submission Clinical Trial Eligibility Criteria","preferredDefinition":"Hematoxylin-and-eosin, or H&E, is a routine staining procedure of tissue sections. This staining method uses two separate dyes, one staining the nucleus and the other staining the cytoplasm and connective tissue. Hematoxylin is a dark purplish dye that stains the chromatin (nuclear material) within the nucleus. Eosin is an orangish-pink to red dye that stains the cytoplasmic material including connective tissue and collagen.:Any material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes, including a sample obtained from a living organism or taken from the biological object after halting of all its life functions. Biospecimen can contain one or more components including but not limited to cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory products.:The act of referring for judgment or consideration by others; the act of handing over something.:Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"C23011:C70699:C25695:C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hematoxylin and Eosin Staining Method","conceptCode":"C23011","definition":"Hematoxylin-and-eosin, or H&E, is a routine staining procedure of tissue sections. This staining method uses two separate dyes, one staining the nucleus and the other staining the cytoplasm and connective tissue. Hematoxylin is a dark purplish dye that stains the chromatin (nuclear material) within the nucleus. Eosin is an orangish-pink to red dye that stains the cytoplasmic material including connective tissue and collagen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Biospecimen","conceptCode":"C70699","definition":"Any material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes, including a sample obtained from a living organism or taken from the biological object after halting of all its life functions. Biospecimen can contain one or more components including but not limited to cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory products.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Submission","conceptCode":"C25695","definition":"The act of referring for judgment or consideration by others; the act of handing over something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"70470C2F-F28A-3519-E053-F662850AC8DC","latestVersionIndicator":"Yes","beginDate":"2018-07-05","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2018-07-05","modifiedBy":"ONEDATA","dateModified":"2018-07-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7046D6E7-B8DE-2B26-E053-F662850ABB6A","latestVersionIndicator":"Yes","beginDate":"2018-07-05","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2018-07-05","modifiedBy":"MAESKEB","dateModified":"2018-07-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Were H&E stained slides submi","type":"Preferred Question Text","description":"Were H&E stained slides submitted or projected to be submitted through APEC14B1 within 13 days of definitive surgery?","url":null,"context":"COG"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Were H&E stained slides submitted or projected to be submitted through APEC14B1?","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"70473530-305E-21A2-E053-F662850A347C","latestVersionIndicator":"Yes","beginDate":"2018-07-05","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2018-07-05","modifiedBy":"SPRINGERL","dateModified":"2018-09-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}